ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
99,306.88
1.00%
S&P 500
5,942.47
0.00%
Dow Jones
42,732.13
0.00%
US Dollar vs Yen
156.5095
-0.64%
Brent Oil
76.74
0.31%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) ニュース

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:TNGX
日付受信時刻ニュースソース見出しコード企業名
2025/01/0221 : 07Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
2024/12/0321 : 00Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
2024/11/2721 : 00Business WireTango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
2024/11/2106 : 24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TNGXTango Therapeutics Inc
2024/11/1909 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/11/0811 : 35Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
2024/11/0711 : 40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/11/0621 : 43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
2024/11/0621 : 23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/11/0621 : 05Business WireTango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
2024/11/0621 : 00Business WireTango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development ProgramNASDAQ:TNGXTango Therapeutics Inc
2024/10/2822 : 22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
2024/10/2610 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/10/2610 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/10/2309 : 50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/10/2309 : 48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/10/2301 : 03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/08/2820 : 00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
2024/08/0720 : 13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
2024/08/0720 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/08/0720 : 00Business WireTango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
2024/06/0806 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/06/0806 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/06/0806 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
2024/06/0705 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/06/0520 : 00Business WireTango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
2024/05/2322 : 18PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
2024/05/2320 : 18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
2024/05/2320 : 00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
2024/05/0820 : 21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNGX

最近閲覧した銘柄

COIN
AVAXUSD
Avalanche
FX
USDGBP
US Dollar vs Sterling
NYSE
AXP
American Express
NYSE
VZ
Verizon Communications
NASDAQ
AAPL
Apple
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
USOTC
ADDYY
Adidas (QX)
NYSE
CVX
Chevron
NASDAQ
TSLA
Tesla
FX
USDJPY
US Dollar vs Yen
NYSE
BAC
Bank of America
COIN
DOGEUSD
Dogecoin
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有